FIELD: medicine.
SUBSTANCE: invention relates to medicine and relates to the use of a nasal composition containing tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine hexapeptide or its pharmaceutically acceptable salt for the treatment of acute respiratory viral diseases of ARVI.
EFFECT: invention provides for the treatment of acute respiratory viral diseases.
9 cl, 9 ex, 3 dwg, 4 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| USING DALARGIN FOR PRODUCING AGENTS FOR TREATING COVID-19 CORONAVIRUS INFECTION | 2020 |
|
RU2728939C1 |
| AGENT FOR THERAPY OF WOUND AND BURN SKIN LESIONS | 2018 |
|
RU2687485C1 |
| STABLE AQUEOUS PHARMACEUTICAL COMPOSITION FOR INHALATIONS CONTAINING A HEXAPEPTIDE | 2020 |
|
RU2739573C1 |
| INHALED HEXAPEPTIDE FOR TREATING RESPIRATORY DISEASES ASSOCIATED WITH INTERLEUKIN-6 | 2020 |
|
RU2737799C1 |
| MEANS FOR PREVENTION OF INTERSTITIAL PNEUMONIA | 2020 |
|
RU2747550C1 |
| INTERFERON-INDUCING AGENT FOR TREATING ACUTE RESPIRATORY VIRAL INFECTIONS (ARVD) | 2010 |
|
RU2470634C2 |
| INTERFERON-INDUCING AGENT FOR TREATING ACUTE RESPIRATORY VIRAL INFECTIONS (ARVD) | 2010 |
|
RU2445094C1 |
| COMPOSITION BASED ON SYNTHETIC PEPTIDES AND LIPIDS FOR C HEPATITIS VACCINE | 2015 |
|
RU2675108C2 |
| USE OF A PHARMACEUTICAL COMPOSITION WITH ANTIOXIDANT, VIRUCIDAL, IMMUNOSTULATING, ANTIHYPOXIC AND ANTI-AGGREGANT EFFECT | 2023 |
|
RU2808445C1 |
| 1-METHYL-2-PHENYLTHIOMETHYL-3-CARBETHOXY-4-DIMETHYLAMINOMETHYL-5- HYDROXY-6 -BROMOINDOLE MESYLATE ELICITING ANTIVIRAL ACTIVITY AND PHARMACEUTICAL COMPOSITION WITH ITS USAGE | 2004 |
|
RU2255086C1 |
